Hoping to get this conversation back on track with (unfortunately) some doomerism:
https://www.cnbc.com/2025/12/11/eli-lillys-weight-loss-drug-retatrutide-clears-first-late-stage-study.html
> The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment. When evaluating only patients who stayed on the drug, the highest dose delivered 28.7% weight loss on average.
That's more potent than Wegovy or Zepbound, though there is this silver lining:
> In a note Thursday, JPMorgan analyst Chris Schott said retatrutide’s tolerability data, or how well patients handle the treatment, is “somewhat worse vs Zepbound, though not surprising, in our view.”